Immuno-evaluation and immunotherapy, new strategy of clinical therapy for chronic hepatitis B / 中华检验医学杂志

ABSTRACT

The immunopathogenosis of chronic hepatitis B is complex. The host immune response plays an important role in determining the turnover of chronic hepatitis B, which is impacted by HBV, host immune system and liver microenvironment. In clinical practice, interferin-α (IFN-α) which has both anti-virus and immuno-regulatary effect wins the advantage over nucleoside analogue. During treatment with INF-α, quantitative HBsAg can predict therapy early which can make physicians modulate individual therapy strategy and achieve better curative effect. To better understand the anti-HBV immune responses to chronic hepatitis B, scientists hope to explore more effective and potential immunotherapeutic strategies against this disease.